LENZ Therapeutics, Inc. (LENZ) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.98
↓-57% vs avg
5yr avg: 2.32
30Y Low1.6·High3.0
ROE
↑
-33.6%
↓+45% vs avg
5yr avg: -61.5%
30Y Low-89%·High-34%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low15.4·High15.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LENZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
LENZ Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $278M | $461M | $614M | $101M | $123M | $488M | — | — |
| Enterprise Value | $253M | $436M | $596M | $66M | $79M | $469M | — | — |
| P/E Ratio → | -3.41 | — | — | — | — | — | — | — |
| P/S Ratio | 14.56 | 24.15 | — | — | 8.21 | — | — | — |
| P/B Ratio | 0.98 | 1.62 | 3.01 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LENZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.85 | — | — | 5.26 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
LENZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
LENZ Therapeutics, Inc. earns an operating margin of -477.5%. A negative ROE of -33.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.8% | 97.8% | — | — | 100.0% | — | — | — |
| Operating Margin | -477.5% | -477.5% | — | — | -69.9% | — | — | — |
| Net Profit Margin | -430.3% | -430.3% | — | — | -72.1% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -33.6% | -33.6% | -89.4% | — | — | — | — | — |
| ROA | -31.5% | -31.5% | -34.8% | -119.3% | -33.1% | -346.0% | -605.9% | -1816.7% |
| ROIC | -30.7% | -30.7% | -152.1% | — | — | — | — | — |
| ROCE | -37.2% | -37.2% | -45.7% | -162.2% | -38.4% | -1591.0% | — | — |
LENZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $25M exceeds total debt of $350000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | 15.43 |
| Net Debt / Equity | — | -0.09 | -0.09 | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | 15.39 |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -337.50 | -0.36 |
Net cash position: cash ($25M) exceeds total debt ($350000)
LENZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
LENZ Therapeutics, Inc.'s current ratio of 13.80x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.63x to 13.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.80 | 13.80 | 20.36 | 3.63 | 4.91 | 14.62 | 0.66 | 0.00 |
| Quick Ratio | 13.80 | 13.80 | 20.36 | 3.63 | 4.91 | 14.62 | 0.66 | 0.00 |
| Cash Ratio | 13.80 | 13.80 | 20.09 | 3.55 | 4.68 | 14.61 | 0.62 | 0.00 |
| Asset Turnover | — | 0.06 | — | — | 0.32 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
LENZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
LENZ Therapeutics, Inc. returns 0.3% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.3% | 0.2% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.3% | 0.2% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Shares Outstanding | — | $29M | $21M | $8M | $8M | $8M | $8M | $8M |
Peer Comparison
Compare LENZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LENZYou | $278M | -3.4 | — | — | 97.8% | -477.5% | -33.6% | -30.7% | — |
 PRPH | $5M | -0.0 | — | — | -2.2% | -570.6% | -188.1% | -59.4% | — |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 AEYE | $100M | -32.4 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RXST | $239M | -6.1 | — | — | 76.6% | -35.8% | -14.0% | -13.3% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 ALC | $31B | 32.3 | 13.7 | 18.0 | 55.2% | 13.1% | 4.5% | 4.0% | 2.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See LENZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LENZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LENZ vs PRPH
Side-by-side business, growth, and profitability comparison vs ProPhase Labs, Inc..
Start ComparisonLENZ — Frequently Asked Questions
Quick answers to the most common questions about buying LENZ stock.
What is LENZ Therapeutics, Inc.'s P/E ratio?
LENZ Therapeutics, Inc.'s current P/E ratio is -3.4x. This places it at the 50th percentile of its historical range.
What is LENZ Therapeutics, Inc.'s ROE?
LENZ Therapeutics, Inc.'s return on equity (ROE) is -33.6%. The historical average is -61.5%.
Is LENZ stock overvalued?
Based on historical data, LENZ Therapeutics, Inc. is trading at a P/E of -3.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are LENZ Therapeutics, Inc.'s profit margins?
LENZ Therapeutics, Inc. has 97.8% gross margin and -477.5% operating margin.